Accessibility Menu
BridgeBio Oncology Therapeutics logo

BridgeBio Oncology Therapeutics(NASDAQ) BBOT

Market Cap$706.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-13%
5 YearN/A
1 YearN/A
1 Month+19%
$8.75
-0.79%
-0.07Today
BridgeBio Oncology Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 8.822026-07-24
BridgeBio Oncology Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.04%USD 8.562026-07-17
1 month+18.55%USD 7.442026-06-24
3 month+0.46%USD 8.782026-04-24
Year to date-29.55%USD 12.522025-12-31
Since inception-13.44%USD 10.192024-02-09

BridgeBio Oncology Therapeutics Financials at a Glance

Market Cap

$706.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$154.10M

EPS (TTM)

-$527.59

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.99 (High)

Price

$8.75

Volume

240,885.878

Open

$9.00

Previous Close

$8.75

Daily Range

$8.72 - $9.26

52-Week Range

$7.00 - $14.87

Estimated Earnings Date

Aug 11, 2026

BBOT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics develops medicines for people with cancer caused by specific gene mutations. Its drugs aim to block cancer growth in patients whose tumors have RAS or PI3Kα gene changes. These treatments are designed for those with hard-to-treat cancers, like certain lung or breast cancers.

What’s in the Medicine Cabinet?

  • BBO-8520: Oral drug for lung cancer with KRAS G12C mutation; in early clinical testing. (0% of revenue)
  • BBO-11818: Oral drug for solid tumors with various KRAS mutations; in early clinical trials. (0% of revenue)
  • BBO-10203: Oral drug for breast and colorectal cancers; targets PI3Kα pathway; in early clinical trials. (0% of revenue)

Growth Spurts and Strategic Moves

  • Spun out from BridgeBio Pharma and became public in August 2025.
  • Raised approximately $450 million through a merger with Helix Acquisition Corp. II in 2025.
  • Entered research and licensing deals with Lawrence Livermore National Security and Leidos Biomedical Research since 2025.
  • Advanced three drug programs into Phase 1 clinical trials by late 2025.

Why BridgeBio Oncology Stands Out

BridgeBio Oncology focuses on drugs that block cancer-driving genes in new ways. Its approach aims to reduce side effects seen with older treatments. The company’s research partnerships help speed up drug discovery and development.

Five Things You Need to Know

  • No revenue reported for 2023, 2024, or 2025.
  • Net loss was $43 million in Q4 2025, up 98.4% from Q4 2024.
  • Cash and equivalents were $272 million in Q4 2025, up 55.8% from Q4 2024.
  • Operating expenses rose 80% to $145.8 million in 2025.
  • Raised $373.5 million from PIPE and de-SPAC deal in August 2025.

Bottom Line

BridgeBio Oncology is a young biotech focused on early-stage cancer drugs. Its growth relies on innovation, partnerships, and raising capital for research.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

92

CEO

Eli M. Wallace, PhD

Website

bbotx.com

Headquarters

South San Francisco, CA 94080, US

BBOT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-61.49%

Return on Capital

-35.23%

Return on Assets

-36.90%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$706.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

80.11M

Volume

240.89K

Avg. Volume

426.35K

Financials (TTM)

Gross Profit

-$186.00K

Operating Income

-$168.86M

EBITDA

-$168.12M

Operating Cash Flow

-$172.07M

Capital Expenditure

-$861.00K

Free Cash Flow

-$172.93M

Cash & ST Invst.

$252.28M

Total Debt

$2.64M

BridgeBio Oncology Therapeutics Performance Analysis

BridgeBio Oncology Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
BridgeBio Oncology Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
BridgeBio Oncology Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00-90.5%
20232023-12-31USD -0.00900.0%
20242024-12-31USD -5,756.41287820560.0%
20252025-12-31USD -4.30-99.9%
BridgeBio Oncology Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-28.7%
Q32025-09-30-57.0%
Q42025-12-3134.2%
Q12026-03-31-8.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$186.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$706.54MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$7.68M

N/A

Employees

92

N/A

Net Income

-$42.11M

-90.9%

EBITDA

-$45.99M

-99.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$252.28M

+85.9%

Total Debt

$2.64M

-0.2%

Accounts Receivable

$146.00K

+265.0%

Inventory

$0.00

N/A

Long Term Debt

$2.11M

-20.3%

Short Term Debt

$538.00K

+8866.7%

Return on Assets

-36.90%

N/A

Return on Invested Capital

-45.10%

N/A

Free Cash Flow

-$35.94M

-4792.3%

Operating Cash Flow

-$35.92M

-4789.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
OCSOculis Holding AG
$11.02-0.99%
PHATPhathom Pharmaceuticals, Inc.
$11.95+4.46%
XNCRXencor, Inc.
$19.86+2.16%
SEPNSepterna Inc
$33.49+1.18%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About BBOT

What is the current price of BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics is trading at $8.75 per share.

What is the 52-week range for BridgeBio Oncology Therapeutics?

Over the past 52 weeks, BridgeBio Oncology Therapeutics has traded between $7.00 and $14.87.

How much debt does BridgeBio Oncology Therapeutics have?

As of the most recent reporting period, BridgeBio Oncology Therapeutics reported total debt of $2.64M.

How much cash does BridgeBio Oncology Therapeutics have on hand?

BridgeBio Oncology Therapeutics reported $52.66M in cash and cash equivalents in its most recent financial results.

What is BridgeBio Oncology Therapeutics’s dividend yield?

BridgeBio Oncology Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services